留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

放射性核素治疗胃肠胰神经内分泌肿瘤:实践与经验

雷蕾 杜涛 欧霞 朱艳 张瑜 张伟

雷蕾, 杜涛, 欧霞, 朱艳, 张瑜, 张伟. 放射性核素治疗胃肠胰神经内分泌肿瘤:实践与经验[J]. 协和医学杂志, 2022, 13(2): 199-202. doi: 10.12290/xhyxzz.2021-0715
引用本文: 雷蕾, 杜涛, 欧霞, 朱艳, 张瑜, 张伟. 放射性核素治疗胃肠胰神经内分泌肿瘤:实践与经验[J]. 协和医学杂志, 2022, 13(2): 199-202. doi: 10.12290/xhyxzz.2021-0715
LEI Lei, DU Tao, OU Xia, ZHU Yan, ZHANG Yu, ZHANG Wei. Treatment of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms by Radionuclide Therapy: Practice and Experience[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 199-202. doi: 10.12290/xhyxzz.2021-0715
Citation: LEI Lei, DU Tao, OU Xia, ZHU Yan, ZHANG Yu, ZHANG Wei. Treatment of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms by Radionuclide Therapy: Practice and Experience[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 199-202. doi: 10.12290/xhyxzz.2021-0715

放射性核素治疗胃肠胰神经内分泌肿瘤:实践与经验

doi: 10.12290/xhyxzz.2021-0715
详细信息
    通讯作者:

    张伟,E-mail:zhangwscd@163.com

  • 中图分类号: R445; R-1

Treatment of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms by Radionuclide Therapy: Practice and Experience

More Information
  • 摘要: 肽受体放射性核素治疗(peptide receptor radionuclide therapy,PRRT)可缓解神经内分泌肿瘤(neuroendocrine neoplasms, NENs)患者症状、提高患者生活质量,且治疗耐受性良好,是NENs目前先进的治疗方法之一。由于该治疗在国内刚起步,如何为PRRT患者提供规范、高效、优质的治疗服务尚存在诸多值得商榷之处。本文在参考国外指南和临床规范的基础之上,结合西南医科大学附属医院开展177Lu-DOTATATE治疗NENs的实践经验,总结相关治疗要点、常见不良反应预防及患者心理干预措施,以期为临床诊疗提供借鉴。
    作者贡献:雷蕾、杜涛、欧霞负责论文初稿撰写及患者治疗;朱艳、张瑜负责文献查阅与治疗流程制订;张伟负责论文设计、内容修订与审核,并参与治疗流程制订。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] 中华医学会消化病学分会胃肠激素与神经内分泌肿瘤学组. 胃肠胰神经内分泌肿瘤诊治专家共识(2020·广州)[J]. 中华消化杂志, 2021, 41: 76-87.
    [2] Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2013, 40: 800-816. doi:  10.1007/s00259-012-2330-6
    [3] 刘会攀, 陈跃. 放射性核素诊治神经内分泌肿瘤的应用进展[J]. 中华核医学与分子影像杂志, 2019, 39: 564-567. doi:  10.3760/cma.j.issn.2095-2848.2019.09.015
    [4] Feijtel D, de Jong M, Nonnekens J. Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward[J]. Curr Top Med Chem, 2020, 20: 2959-2969. doi:  10.2174/1568026620666200226104652
    [5] Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate[J]. J Nucl Med, 2014, 55: 183-190. doi:  10.2967/jnumed.113.125336
    [6] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. doi:  10.1056/NEJMoa1607427
    [7] Nicolini S, Severi S, Ianniello A, et al. Investigation of receptor radionuclide therapy with (177)Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 923-930. doi:  10.1007/s00259-017-3925-8
    [8] Perren A, Couvelard A, Scoazec JY, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification[J]. Neuroendocrinology, 2017, 105: 196-200. doi:  10.1159/000457956
    [9] Costa F, Gumz B. Octreotide - A Review of its Use in Treating Neuroendocrine Tumours[J]. Eur Endocrinol, 2014, 10: 70-74.
    [10] Calais PJ, Turner JH. Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors[J]. Ann Nucl Med, 2014, 28: 531-539. doi:  10.1007/s12149-014-0843-8
    [11] 王国慧, Lau E, Shakher R, 等. 177Lu-octreotate治疗神经内分泌胃肠胰腺肿瘤的SPECT显像研究[J]. 中华核医学杂志, 2007, 27: 313-314. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHHY200705031.htm
    [12] Erbas B, Tuncel M. Renal Function Assessment During Peptide Receptor Radionuclide Therapy[J]. Semin Nucl Med, 2016, 46: 462-478. doi:  10.1053/j.semnuclmed.2016.04.006
    [13] Shaheen S, Moradi F, Gamino G, et al. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities[J]. Curr Treat Options Oncol, 2020, 21: 25. doi:  10.1007/s11864-020-0711-9
    [14] Makis W, McCann K, McEwan AJ. The Challenges of Treating Paraganglioma Patients with 177Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols[J]. Nucl Med Mol Imaging, 2015, 49: 223-230. doi:  10.1007/s13139-015-0332-6
    [15] 范素云, 柴丽, 贾彦彦, 等. 131I治疗期间甲状腺癌患者未满足的照顾需求分析[J]. 中华核医学与分子影像杂志, 2018, 38: 422-424.
  • 加载中
计量
  • 文章访问数:  94
  • HTML全文浏览量:  6
  • PDF下载量:  24
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-10-28
  • 录用日期:  2021-12-29
  • 网络出版日期:  2021-12-30
  • 刊出日期:  2022-03-30

目录

    /

    返回文章
    返回